Volume 25, Number 1—January 2019
Synopsis
Clinical and Radiologic Characteristics of Human Metapneumovirus Infections in Adults, South Korea
Table 1
Clinical characteristics of patients infected with human metapneumovirus, South Korea*
Characteristic | Immunocompetent | Solid tumors† | SOT | HCT | HM | Steroid use | Total |
---|---|---|---|---|---|---|---|
Total |
459 (54) |
174 (20) |
59 (7) |
9 (1) |
58 (7) |
90 (11) |
849 |
Age, y |
67 (56–75) |
62 (53–70) |
56 (49–62) |
54 (32–63) |
60 (47–67) |
67 (52–75) |
64 (53–73) |
Sex | |||||||
M | 229 (50) | 89 (51) | 25 (42) | 6 (67) | 24 (41) | 50 (56) | 442 (52) |
F | 230 (50) | 85 (49) | 34 (58) | 3 (33) | 34 (59) | 40 (44) | 407 (48) |
Smoking status | |||||||
Never | 326 (71) | 104 (60) | 43 (73) | 5 (56) | 40 (69) | 47 (52) | 565 (67) |
Former | 99 (22) | 63 (36) | 16 (27) | 3 (33) | 14 (24) | 38 (42) | 233 (6) |
Current |
34 (7) |
7 (4) |
0 |
1 (11) |
4 (7) |
5 (6) |
51 (27) |
BP, mm Hg | |||||||
Systolic | 134 (120–152) | 124 (115–137) | 131 (116–146) | 130 (113–136) | 128 (120–140) | 134 (120–151) | 131 (119–147) |
Diastolic |
80 (73–90) |
80 (73–88) |
82 (74–92) |
88 (82–90) |
82 (76–90) |
82 (74–90) |
80 (73–90) |
Temperature, °C | 36.6 (36.4–37.2) | 36.6 (36.4–37.2) | 36.4 (36.2–36.8) | 36.7 (36.5–37.7) | 36.5 (36.2–36.7) | 36.6 (36.3–36.9) | 36.6 (36.4–37.1) |
Temperature, >37°C |
70 (15) |
25 (14) |
4 (7) |
3 (33) |
5 (9) |
16 (18) |
123 (14.5) |
Heart rate, beats/min | 83 (70–99) | 88 (78–103) | 82 (73–91) | 100 (90–110) | 87 (77–100) | 93 (84–106) | 87 (74–100) |
Respiratory rate, breaths/min |
20 (18–22) |
20 (18–20) |
18 (18–20) |
22 (20–27) |
20 (18–22) |
22 (20–24) |
20 (18–22) |
Body mass index, kg/m2 | 23.2 (20.4–25.9) | 23.1 (20.3–25.5) | 23.2 (21.3–25.1) | 20.2 (17.0–25.1) | 22.4 (20.5–25.2) | 22.6 (20.2–24.4) | 23.1 (20.4–25.5) |
Hypertension | 239 (52) | 71 (41) | 47 (80) | 3 (33) | 22 (38) | 51 (57) | 433 (51) |
Diabetes mellitus |
157 (34) |
42 (24) |
44 (75) |
4 (44) |
20 (35) |
29 (32) |
296 (35) |
Location of patients‡ | |||||||
Outpatient clinic | 22 | 1 | 2 | 0 | 0 | 2 | 27 |
Hospitalized | 131 | 137 | 21 | 3 | 24 | 35 | 351 |
ED |
306 |
36 |
36 |
6 |
34 |
53 |
471 |
Type of infection | |||||||
CA | 415 (90) | 150 (86) | 51 (86) | 7 (88) | 47 (81) | 84 (93) | 756 (89) |
Nosocomial |
44 (10) |
24 (14) |
8 (14) |
2 (22) |
11 (19) |
6 (7) |
93 (11) |
URI | 126 (28) | 68 (39) | 30 (51) | 1 (11) | 20 (35) | 27 (30) | 270 (32) |
LRD |
333 (73) |
106 (61) |
29 (49) |
8 (89) |
38 (66) |
63 (70) |
579 (68) |
Initial CRP level at hospital admission, mg/L |
4.3
(1.5–9.9) |
6.5
(2.6–13.3) |
4.6
(1.0–7.7) |
10.6
(5.5–19.7) |
5.8
(2.8–12.0) |
4.4
(1.9–4.4) |
4.9
(1.8–11.0) |
Leukocyte count at diagnosis, × 103/μL | 7.7 (5.5–10.5) | 5.4 (2.8–8.7) | 8.5 (4.8–10.6) | 12.0 (6.5–13.6) | 4.8 (2.3–7.4) | 8.3 (5.7–11.5) | 7.2 (4.9–10.3) |
>10 | 128 (28) | 33 (19) | 16 (27) | 5 (56) | 7 (12) | 34 (38) | 223 (26) |
<10 |
331 (72) |
141 (81) |
43 (73) |
4 (44) |
51 (88) |
56 (62) |
626 (74) |
Neutrophil count at diagnosis, × 103/μL§ | 5.5 (3.4–8.3) | 3.9 (1.7–6.5) | 6.1 (3.3–8.5) | 7.9 (5.9–9.5) | 2.9 (1.3–5.1) | 6.2 (3.9–9.6) | 5.1 (3.0–8.1) |
>5.0 | 252 (55) | 67 (39) | 35 (59) | 6 (67) | 14 (24) | 56 (62) | 430 (51) |
<5.0 |
205 (45) |
106 (61) |
24 (41) |
1 (11) |
42 (72) |
32 (36) |
410 (48) |
Lymphocyte count at diagnosis, × 103/μL§ | 1.3 (0.9–1.8) | 0.8 (0.5–1.3) | 1.0 (0.6–1.4) | 2.9 (0.7–4.2) | 0.8 (0.4–1.7) | 1.1 (0.7–1.6) | 1.1 (0.7–1.6) |
>0.7 | 380 (83) | 97 (56) | 41 (70) | 5 (56) | 33 (57) | 65 (72) | 621 (73) |
<0.7 |
77 (17) |
76 (44) |
18 (31) |
2 (22) |
23 (40) |
23 (26) |
219 (26) |
Platelet count, × 103/μL |
193
(145–243) |
149
(101–223) |
166
(116–231) |
82
(35–187) |
86
(36–146) |
198
(143–245) |
176
(124.5–233) |
Blood urea nitrogen, mg/Dl | 14 (10–22) | 13 (9–19) | 21 (14–31) | 15.0 (8.5–27.0) | 14.5 (10–20.3) | 15 (11–23.5) | 14.0 (10.0–21.0) |
Creatinine, mg/dL | 0.8 (0.7–1.1) | 0.8 (0.6–1.0) | 1.3 (1.0–1.8) | 0.9 (0.7–1.4) | 0.8 (0.6–1.2) | 0.8 (0.6–1.1) | 0.8 (0.7–1.1) |
Procalcitonin, ng/mL | 0.2 (0.1–1.2) | 0.2 (0.1–0.7) | 0.2 (0.1–1.2) | 0.2 (0.1–1.1) | 0.2 (0.1–0.6) | 0.2 (0.1–0.9) | 0.2 (0.1–0.9) |
*Values are no. (%) or median (interquartile range) unless otherwise indicated. BP, blood pressure; CA, community acquired; CRP, C-reactive protein; ED, emergency department; HCT, hematologic stem cell transplantation; HM, hematologic malignancy; HMPV, human metapneumovirus; LRD, lower respiratory tract disease; SOT, solid organ transplants; URI, upper respiratory tract infection.
†Patients with solid tumors were given chemotherapy within 6 mo.
‡Locations at which patients were tested for HMPV.
§Detailed laboratory results, including neutrophil and lymphocyte counts, were unavailable for 9 patients who visited outpatient clinics